These changes were accompanied by a significant improvement in the pathological diagnostic and prognostic classification of BC, which included detailed histomorphological assessment in addition to evaluation of the hormone receptor and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene NR4A1 and breast cancer.